## **Core Concept**
The question tests knowledge of muscarinic receptor antagonists, specifically those targeting the M3 receptor subtype, and their application in treating overactive bladder. Muscarinic receptors, particularly M3, play a significant role in bladder smooth muscle contraction. Overactive bladder is characterized by urgency, with or without urge incontinence, usually accompanied by frequency and nocturia.

## **Why the Correct Answer is Right**
Solifenacin is a muscarinic receptor antagonist with a higher affinity for the M3 receptor subtype. By blocking M3 receptors in the bladder, solifenacin reduces bladder smooth muscle contraction, thereby decreasing the symptoms of overactive bladder, such as urgency and urge incontinence. Its selectivity for M3 over other muscarinic receptor subtypes helps minimize side effects related to other receptor subtypes.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Tolterodine is indeed a muscarinic receptor antagonist used for overactive bladder but is not specified to have a high selectivity for the M3 subtype compared to solifenacin.
* **Option B:** Trospium chloride is another muscarinic antagonist used for overactive bladder treatment. However, it is not specifically known for M3 selectivity in the same context as solifenacin.
* **Option D:** Darifenacin is also a muscarinic receptor antagonist with some selectivity for the M3 subtype but is less commonly referenced for this indication compared to solifenacin.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that solifenacin is specifically used for the treatment of overactive bladder and has a favorable side effect profile due to its M3 selectivity. This makes solifenacin a preferred option for patients with overactive bladder who may need to avoid side effects associated with non-selective muscarinic antagonists.

## **Correct Answer:** . Solifenacin.